Scholars Central

Conference abstractPublished 15 May 2017

CMC considerations for biosimilar drug development

Authors: Ulrike Konrad

Karl Ruprecht UniversitÃ?¤t, Germany

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Developing a biosimilar from a CMC perspective is a scientific and risk based approach and not a list with checkboxes to be ticked off. Following the quality strategy, the biosimilarity cannot be tested in the clinical trials but must be demonstrated on the drug substance and product level. For this, there are typical road maps always starting with a quality target product profile of the originator molecules. This talk will focus on typical analytical modules on the road map also touching the comparison of degradation profiles and impurities of biosimilar and originator molecules in a side-by-side analytical situation. All that must be adapted to the companyâÂ?Â?s strategy for market, time for development, budget and partners. Typical examples will be presented combined with pitfalls that companies are facing during the development.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Similar by topic

More from this journal

The newest in Journal of Bioanalysis & Biomedicine.

All its articles

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Bioanalysis & Biomedicine
  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “Ulrike Konrad”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels